Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPCN 1148 in Male Subjects With Cirrhosis and Sarcopenia
NCT04874350Phase 2Completed
- Sponsor
- Lipocine Inc
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LPCN 1148 in Sarcopenia, hepatic encephalopathy (HE), sponsored by Lipocine Inc. Started Nov 2021; status: completed.
02
Drugs
LPCN 1148
03
Conditions
Sarcopeniahepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04874350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874350.